image credit- shutterstock
German firm Molecular Health GmbH will collaborate with South Korean startup EONE-Diagnomics Genome Center (EDGC) to help its healthcare provider customers identify personalized treatment options for cancer patients.
The collaboration is intended to establish leadership in the fast-growing precision medicine market for liquid biopsy. Therefore, the two partners combine two major proprietary technologies, Molecular Health’s MH Guide and EDGC’s ONCOCATCH-CDx. This allows comprehensive genomic tumor profiling to guide treatment in solid tumors.
As part of the cooperation, EDGC aims to utilize Molecular Health’s MH Guide, an analysis software that supports oncologists and molecular pathologists in the interpretation of large molecular datasets. Independent of the sequencing technology used, MH Guide can make complex datasets readable, and automatically identify genetic variants that are relevant for the treatment of cancer patients.
EDGC is an international joint venture based in South Korea that develops leading-edge technology for genome analysis and precision as well as personalized medicine. With ONCOCATCH-CDx the research and development company developed a unique noninvasive biopsy for early diagnosis, companion diagnostics and monitoring of all-stage cancer.
